Clinical Evidence: How Wegovy and Mounjaro Compare in UK Trials
Wegovy vs Mounjaro Dose Comparison: Understanding the Weight Loss Results UK Patients Achieve
When comparing Wegovy and Mounjaro for weight management, UK patients often focus on the clinical evidence from published trials rather than marketing claims. The STEP trial programme for Wegovy demonstrated that patients taking semaglutide alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks in the STEP 1 study. Mounjaro's SURMOUNT trials showed impressive results through its dual GIP/GLP-1 mechanism, though direct head-to-head comparisons between the two treatments haven't been conducted in identical trial populations.
The key difference lies in their dosing schedules and mechanisms of action. Wegovy follows a 5-dose escalation protocol (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg maintenance) whilst Mounjaro uses 4 doses (2.5mg, 5mg, 10mg, 15mg). Both treatments require careful dose escalation to minimise gastrointestinal side effects, but their different active ingredients mean some patients may respond better to one approach over the other. This is why clinical assessment remains crucial when choosing between these prescription-only medicines.
Wegovy Mounjaro Dose Comparison Pricing: Complete UK Cost Breakdown
Understanding the true cost of each treatment helps UK patients make informed decisions about their weight loss journey. For Wegovy, EverydayMeds pricing starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. New customers can apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices. Our bundle options provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99.
Mounjaro pricing follows a different structure due to its distinct dosing protocol, though both treatments represent significant monthly investments in your health. The key advantage of our bundle system lies in convenience rather than pure cost savings—you secure Reliable Supply, reduce ordering frequency, and receive everything in one temperature-controlled delivery. This proves particularly valuable given current supply chain challenges affecting weight management medications across the UK market.
Clinical Evidence from STEP Trials: What Wegovy Mounjaro Dose Comparison Studies Reveal
The published evidence from Wilding et al., NEJM, 2021, provides the foundation for understanding Wegovy's efficacy in real-world settings. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss in STEP 1, with STEP 3 showing 16% when combined with intensive behavioural therapy. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management.
STEP 5 data proved particularly relevant for UK patients considering long-term treatment, showing sustained clinically studied weight loss at 2 years. However, the extension studies also revealed that patients regained approximately two-thirds of lost weight within one year of stopping treatment, reinforcing that weight management represents a long-term commitment rather than a short-term intervention.
How Wegovy Works: The Science Behind This Wegovy Mounjaro Dose Comparison
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone responsible for regulating blood sugar and appetite. When you inject Wegovy once weekly, it binds to GLP-1 receptors in your brain's appetite control centres, promoting feelings of fullness after smaller meals and potentially reducing food cravings throughout the day. This mechanism differs from Mounjaro's tirzepatide, which activates both GLP-1 and GIP receptors for a dual approach. The gradual dose escalation allows your body to adapt to these hormonal changes whilst minimising common gastrointestinal side effects like nausea or vomiting. Understanding these mechanistic differences helps explain why some patients respond better to one treatment approach when comparing Wegovy and Mounjaro outcomes.
Ordering Process: Getting Started with Your Wegovy Mounjaro Dose Comparison Journey
EverydayMeds streamlines access to both Wegovy and Mounjaro through our regulated online service, eliminating lengthy NHS waiting lists whilst maintaining clinical safety standards. The process begins with a comprehensive 3-minute clinical assessment covering your medical history, current medications, weight management goals, and any contraindications that might affect treatment selection. Our qualified prescribers review your application within 3 working days (or 24 hours with express service), determining which treatment suits your individual circumstances. Once approved, we dispatch your medication via next-day cold-chain delivery, ensuring temperature-controlled transport that maintains drug stability. This efficient system connects you with prescription-only weight management medication whilst preserving the clinical oversight essential for safe, effective treatment.
Storage and Practical Considerations: Wegovy Mounjaro Dose Comparison Logistics
Practical storage requirements often influence patient preference when comparing Wegovy and Mounjaro for long-term weight management. Wegovy pens must be stored at 2-8°C in your refrigerator before first use, but offer superior travel convenience by remaining stable for up to 6 weeks at room temperature below 30°C once removed from cold storage. This compares favourably to Mounjaro's 21-day room temperature limit, making Wegovy more suitable for extended travel or irregular schedules. The FlexTouch pen design requires no mixing or preparation—simply attach a new needle, dial your prescribed dose, and inject subcutaneously into your thigh, abdomen, or upper arm. Dose escalation follows a strict 4-week schedule for each strength, and skipping doses isn't recommended as this increases side effect risk when resuming treatment.
UK Patient Outcomes: Real-World Wegovy Mounjaro Dose Comparison Results
Beyond clinical trial data, real-world evidence from UK patients provides valuable insights into how Wegovy and Mounjaro perform in everyday settings. NHS pilot programmes and specialist weight management clinics report that patient response varies significantly between individuals, with some achieving excellent results on lower Wegovy doses whilst others require progression to 2.4mg maintenance therapy. The gradual dose escalation proves crucial for tolerability—patients who rush the process often experience increased nausea, vomiting, or gastroparesis that forces treatment discontinuation.
Successful outcomes typically involve patients who combine their prescribed medication with sustainable lifestyle modifications rather than viewing injection therapy as a standalone solution. UK healthcare providers emphasise that both Wegovy and Mounjaro work best when integrated into comprehensive weight management programmes including nutritional counselling, regular exercise, and ongoing medical monitoring throughout treatment.
Making Your Decision: Expert Guidance on Wegovy Mounjaro Dose Comparison Selection
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns with your medical history, lifestyle preferences, and weight management goals. Factors influencing this decision include your previous experience with GLP-1 medications, tolerance for injection frequency, budget considerations, and any existing medical conditions that might favour one mechanism over another. Our clinical team at GPhC #9012878 provides ongoing support throughout your treatment journey, monitoring progress and adjusting protocols based on your individual response. Remember that starting with code FIRST40 (new customers) or DOSE25 (returning customers) ensures you receive our best available pricing from day one. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and take the first step towards evidence-based weight management with expert pharmaceutical oversight.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
